Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	97570
Country	India

Received	2024-06-02 17:55
Peer-Review Started	2024-06-02 17:55
To Make the First Decision
Return for Revision	2024-08-15 19:45
Revised	2024-08-22 21:47
Second Decision	2024-08-28 02:41
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2024-08-28 10:19
Articles in Press	2024-08-28 10:19
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-08-29 07:48
Publish the Manuscript Online	2024-09-03 08:54

ISSN	2150-5349 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Transplantation
Manuscript Type	Minireviews
Article Title	Downstaging of advanced hepatocellular carcinoma followed by liver transplantation using immune checkpoint inhibitors: Where do we stand?
Manuscript Source	Invited Manuscript
All Author List	Hirak Pahari, Javid A Peer, Shikhar Tripathi, Suresh K Singhvi and Ushast Dhir
Funding Agency and Grant Number
Corresponding Author	Hirak Pahari, DNB, MBBS, Surgeon, Department of Liver Transplant and Hepatobiliary Surgery, Sir Ganga Ram Hospital, Old Rajinder Nagar, New Delhi 110060, Delhi, India. hirak.pahari@gmail.com
Key Words	Hepatocellular carcinoma; Liver transplant; Downstaging; Atezolizumab; Nivolumab; Immune checkpoint inhibitors
Core Tip	The advent of immune checkpoint inhibitors as a downstaging therapy has been followed with great interest since the results of the IMBRAVE study, especially for multifocal hepatocellular carcinoma beyond criteria and certain cases with portal vein tumor thrombosis. Multiple case reports have shown benefit but with a degree of caution. Our review aims to identify the key points and recommendations for the safe usage of these life-saving immunomodulators in the setting of liver transplantation using the current available literature.
Publish Date	2024-09-03 08:54
Citation	<p>Pahari H, Peer JA, Tripathi S, Singhvi SK, Dhir U. Downstaging of advanced hepatocellular carcinoma followed by liver transplantation using immune checkpoint inhibitors: Where do we stand? <i>World J Gastrointest Pharmacol Ther</i> 2024; 15(5): 97570</p>
URL	https://www.wjgnet.com/2150-5349/full/v15/i5/97570.htm
DOI	https://dx.doi.org/10.4292/wjgpt.v15.i5.97570

Full Article (PDF)	WJGPT-15-97570-with-cover.pdf
Manuscript File	97570_Auto_Edited_004100.docx
Answering Reviewers	97570-answering-reviewers.pdf
Audio Core Tip	97570-audio.mp4
Conflict-of-Interest Disclosure Form	97570-conflict-of-interest-statement.pdf
Copyright License Agreement	97570-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	97570-non-native-speakers.pdf
Peer-review Report	97570-peer-reviews.pdf
Scientific Misconduct Check	97570-scientific-misconduct-check.png
Scientific Editor Work List	97570-scientific-editor-work-list.pdf
CrossCheck Report	97570-crosscheck-report.pdf
CrossCheck Report	97570-crosscheck-report.png